Literature DB >> 10867593

Decline in FEV(1) in community-based older volunteers with higher levels of neutrophil elastase in bronchoalveolar lavage fluid.

T Betsuyaku1, M Nishimura, K Takeyabu, M Tanino, K Miyamoto, Y Kawakami.   

Abstract

BACKGROUND: Neutrophil elastase (NE) is thought to be one of the key proteinases in the development of chronic obstructive pulmonary disease (COPD). Previously, we have shown that the NE-alpha1-proteinase inhibitor (NE-alpha1PI) complex in bronchoalveolar lavage (BAL) fluid was markedly elevated in asymptomatic smokers who had subclinical emphysema on CT scans. We proposed that excessive NE-alpha1PI complex in BAL fluid was a factor which might differentiate smokers who were developing emphysema from others.
OBJECTIVE: In this study, we addressed the question of whether elevated levels of the NE-alpha1PI complex in BAL fluid are linked to the accelerated decline in pulmonary functions in those subjects.
METHODS: We conducted a follow-up study to analyze the decline in FEV(1) for 4.3 years on average for 26 community-based volunteers who had received pulmonary function tests, CT scans and BAL. The levels of the NE-alpha1PI complex in BAL fluid and in plasma was measured.
RESULTS: Neither pulmonary function measurements nor the presence of emphysema on CT scans could predict the decline in FEV(1). The number of inflammatory cells in BAL fluid was also not an indicator of progression. By contrast, subjects with higher levels of the NE-alpha1PI complex in BAL fluid had a significantly accelerated decline in FEV(1) compared to those with lower levels.
CONCLUSION: These data seem to support the hypothesis that NE in the lung is related to the onset and/or progression of COPD. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10867593     DOI: 10.1159/000029508

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  8 in total

Review 1.  Chronic obstructive pulmonary disease - part 2: pathology and biochemistry of emphysema.

Authors:  J C Hogg; R M Senior
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

Review 2.  Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease.

Authors:  Caroline A Owen
Journal:  Proc Am Thorac Soc       Date:  2005

3.  Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung.

Authors:  Kristopher R Genschmer; Derek W Russell; Charitharth Lal; Tomasz Szul; Preston E Bratcher; Brett D Noerager; Mojtaba Abdul Roda; Xin Xu; Gabriel Rezonzew; Liliana Viera; Brian S Dobosh; Camilla Margaroli; Tarek H Abdalla; Robert W King; Carmel M McNicholas; J Michael Wells; Mark T Dransfield; Rabindra Tirouvanziam; Amit Gaggar; J Edwin Blalock
Journal:  Cell       Date:  2019-01-10       Impact factor: 41.582

Review 4.  Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies.

Authors:  Uros V Djekic; Amit Gaggar; Nathaniel M Weathington
Journal:  Pharmacol Ther       Date:  2008-10-31       Impact factor: 12.310

Review 5.  Systematic review of the evidence relating FEV1 decline to giving up smoking.

Authors:  Peter N Lee; John S Fry
Journal:  BMC Med       Date:  2010-12-14       Impact factor: 8.775

6.  Annual change in FEV1 in elderly 10-year survivors with established chronic obstructive pulmonary disease.

Authors:  Masaru Suzuki; Hironi Makita; Satoshi Konno; Kaoruko Shimizu; Yasuyuki Nasuhara; Katsura Nagai; Yasushi Akiyama; Satoshi Fuke; Hiroshi Saito; Takeshi Igarashi; Kimihiro Takeyabu; Masaharu Nishimura
Journal:  Sci Rep       Date:  2019-02-14       Impact factor: 4.379

Review 7.  Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease.

Authors:  Caroline A Owen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 8.  The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals.

Authors:  Danielle M Dunlea; Laura T Fee; Thomas McEnery; Noel G McElvaney; Emer P Reeves
Journal:  J Inflamm Res       Date:  2018-03-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.